Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
PHASE1CompletedINTERVENTIONAL
Timeline
Start Date
October 31, 2002
Primary Completion Date
October 31, 2004
Conditions
LeukemiaLymphoma
Interventions
BIOLOGICAL
lumiliximab
Trial Locations (1)
10021
Memorial Sloan-Kettering Cancer Center, New York
All Listed Sponsors
collaborator
National Cancer Institute (NCI)
NIH
lead
Memorial Sloan Kettering Cancer Center
OTHER
NCT00058396 - Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Biotech Hunter | Biotech Hunter